Potent, selective platelet-activating factor (PAF) receptor antagonist (Ki
= 16.3 nM). Displays anti-inflammatory, antiangiogenic and anticancer activity. Inhibits growth and proliferation of MCF-7 breast cancer cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Characterization of PAF receptors on human neutrophils using the specific antagonist, WEB 2086.
Dent et al.
FEBS Lett., 1989;244:365
Effects of WEB 2086 on the protective role of preconditioning against arrhythmias in rats.
Sariahmetoglu et al.
Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086.
Cellai et al.
The citations listed below are publications that use Tocris products. Selected citations for WEB 2086 include:
Showing Results 1 - 4 of 4